A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
收藏Mendeley Data2024-01-31 更新2024-06-27 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009372/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (IV) administration of daratumumab (Dara IV) in terms of the overall response rate (ORR) and maximum trough concentration (Ctrough).
创建时间：
2024-01-31
